LOKELMATM▼ Sodium Zirconium Cyclosilicate
SWIFT* K+ REDUCTION AFTER ONE HOUR.1,2
SUSTAINED K+ CONTROL FOR UP TO ONE YEAR
WHEN USED AS A MAINTENANCE THERAPY.†1
NOW IN YOUR HANDS.
New, highly-selective LOKELMA (sodium zirconium cyclosilicate)
is indicated for the treatment of hyperkalaemia in adult patients1
*In an emergency situation, standard of care should be used in line with local or national guidelines
†Clinical trials with LOKELMA have not included exposure longer than one year
- For adult patients with hyperkalaemia, LOKELMA (sodium zirconium cyclosilicate) is highly selective and proven
to significantly reduce potassium (K+) levels after 1 hour*1,2
- 88% of patients achieved normokalaemia at 48 hours1
- Once-daily maintenance dosing of LOKELMA sustains normokalaemia (3.5 - 5.0 mmol/L) for up to one year†1
*In an emergency situation, standard of care should be used in line with local or national guidelines.
†Clinical trials with LOKELMA have not included exposure longer than 1 year.
Mechanism of Action
Novel, selective K+ capture3
LOKELMA captures K+ throughout the entire gastrointestinal (GI) tract and reduces the concentration of free K+ in the GI lumen, thereby increasing faecal K+ excretion to reduce serum levels of K+.1
Lattice structure uniquely designed to preferentially capture K+3
- LOKELMA is a non-absorbed, non-polymer inorganic powder with a uniform micropore structure that preferentially captures K+ in exchange for Hydrogen and Sodium cations (Na+)1
- LOKELMA is highly selective for K+ ions, even in the presence of other cations, such as Calcium (Ca+) and Magnesium (Mg2+), in vitro‡1
- LOKELMA contains less than 8% Na+ by total weight. For example, one 5 g dose of LOKELMA contains 400 mg of Na+3
‡In vitro data suggest LOKELMA works at different pHs found along the GI tract.
Adapted from Stavros F, et al. PLoS One. 2014;9(12):e114686.
- Not systemically absorbed1
- No effect on serum calcium or magnesium concentrations1
- No effect on urinary Na+ excretion1